A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Stopped early · Phase 1/Phase 2

Conditions studied: Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung

In brief

A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.

Key facts

Study ID

NCT05397171

Run by

AstraZeneca

People needed

17

Starts

2022-06-07

Expected to finish

2023-06-06

Last updated by the study team

2024-10-01

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Atlanta, Georgia, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Providence, Rhode Island, United States
• Research Site — Seattle, Washington, United States
• Research Site — Ottawa, Ontario, Canada
• Research Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.